Earnings Feed
Sign Up
Home/Filings/3/0000899243-21-000972
3//SEC Filing

F2 MC, LLC 3

Accession 0000899243-21-000972

CIK 0001789972other
View on SEC.govCompany Profile

Filed

Jan 6, 7:00 PM ET

Accepted

Jan 7, 8:32 PM ET

Size

37.7 KB

Accession

0000899243-21-000972

Insider Transaction Report

Form 3
Period: 2021-01-07
Cullinan Management, Inc.CGEM
Jovan-Embiricos Morana
Director10% Owner
Holdings

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (35,529 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,912,345 underlying)

  • Common Stock

    112,507

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (104,845 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (639,295 underlying)

  • Series Seed Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,136,525 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (214,798 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (455,338 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (182,135 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (143,198 underlying)
F2 MC, LLC
10% Owner
Holdings

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (143,198 underlying)

  • Common Stock

    112,507

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (35,529 underlying)

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (104,845 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (182,135 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series Seed Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,136,525 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,912,345 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (639,295 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (455,338 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (214,798 underlying)
Globeways Holdings Ltd
10% Owner
Holdings

  • Common Stock

    112,507

  • Series Seed Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,136,525 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,912,345 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (639,295 underlying)

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (35,529 underlying)

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (104,845 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (455,338 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (182,135 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (143,198 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (214,798 underlying)
F2 MG Ltd
10% Owner
Holdings

  • Common Stock

    112,507

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (104,845 underlying)

  • Series Seed Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,136,525 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (143,198 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (214,798 underlying)

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (35,529 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,912,345 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (639,295 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (455,338 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (182,135 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)
F2 Bio TD, LLC
10% Owner
Holdings

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,912,345 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (455,338 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (143,198 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (214,798 underlying)

  • Common Stock

    112,507

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (35,529 underlying)

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (104,845 underlying)

  • Series Seed Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,136,525 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (639,295 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (182,135 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)
F2 Vision SCS
10% Owner
Holdings

  • Common Stock

    112,507

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (35,529 underlying)

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (104,845 underlying)

  • Series Seed Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,136,525 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,912,345 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (639,295 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (455,338 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (182,135 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (143,198 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (214,798 underlying)
F2 Bioscience I 2017 Ltd
10% Owner
Holdings

  • Common Stock

    112,507

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (35,529 underlying)

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (104,845 underlying)

  • Series Seed Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,136,525 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,912,345 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (639,295 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (455,338 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (182,135 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (143,198 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (214,798 underlying)
F2 - TPO Investments LLC
10% Owner
Holdings

  • Common Stock

    112,507

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (35,529 underlying)

  • Stock Option (Right to Buy)

    Exercise: $4.30Exp: 2030-10-28→ Common Stock (104,845 underlying)

  • Series Seed Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,136,525 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,912,345 underlying)

  • Series A Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (639,295 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (455,338 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (182,135 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (143,198 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (71,599 underlying)

  • Series C Convertible Preferred Stock

    (indirect: See footnote)
    → Common Stock (214,798 underlying)
Footnotes (9)
  • [F1]25% of the shares vested on March 8, 2018, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
  • [F2]Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 1-for-7.0390 basis into the number of common stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock has no expiration date.
  • [F3]These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  • [F4]These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  • [F5]These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  • [F6]These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  • [F7]These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  • [F8]These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  • [F9]These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Documents

2 files

Issuer

Cullinan Management, Inc.

CIK 0001789972

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001838426

Filing Metadata

Form type
3
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 8:32 PM ET
Size
37.7 KB
View on SEC.gov